Antimicrobial activity of ceftobiprole against Gram-negative and Gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study
Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most Gram-negative bacilli including Pseudomonas aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested aga...
Saved in:
Published in | The Brazilian journal of infectious diseases Vol. 15; no. 4; pp. 339 - 348 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Brazil
Elsevier Editora Ltda
01.07.2011
Contexto Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most Gram-negative bacilli including Pseudomonas aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested against bacterial isolates recently collected from Brazilian private hospitals. A total of 336 unique bacterial isolates were collected from hospitalized patients between February 2008 and August 2009. Each hospital was asked to submit 100 single bacterial isolates responsible for causing blood, lower respiratory tract or skin and soft tissue infections. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using CLSI microdilution method at a central laboratory. The CLSI M100-S21 (2011) was used for interpretation of the antimicrobial susceptibility results. Among the 336 pathogens collected, 255 (75.9%) were Gram-negative bacilli and 81 (24.1%) were Gram-positive cocci. Although ceftobiprole MIC50 values for oxacillin resistant strains were two-fold higher than for methicillin susceptible S. aureus, ceftobiprole inhibited 100% of tested S. aureus at MICs≤4μg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90, 0.5/1μg/mL), and P. aeruginosa (MIC50/90, 1/2μg/mL). Resistance to broad-spectrum cephalosporins varied from 55.3–68.5% and 14.3–28.5% among E. coli and Klebsiella spp. isolates, respectively; with ceftobiprole MIC50>6μg/mL for both species. Our results showed that ceftobiprole has potent activity against staphylococci and E. faecalis, which was superior to that of vancomycin. Our data also indicates that ceftobiprole demonstrated potency comparable to that of cefepime and ceftazidime against key Gram-negative species. |
---|---|
AbstractList | Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most gram-negative bacilli including Pseudomonas aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested against bacterial isolates recently collected from Brazilian private hospitals. A total of 336 unique bacterial isolates were collected from hospitalized patients between February 2008 and August 2009. Each hospital was asked to submit 100 single bacterial isolates responsible for causing blood, lower respiratory tract or skin and soft tissue infections. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using CLSI microdilution method at a central laboratory. The CLSI M100-S21 (2011) was used for interpretation of the antimicrobial susceptibility results. Among the 336 pathogens collected, 255 (75.9%) were gram-negative bacilli and 81 (24.1%) were gram-positive cocci. Although ceftobiprole MIC50 values for oxacillin resistant strains were two-fold higher than for methicillin susceptible S. aureus, ceftobiprole inhibited 100% of tested S. aureus at MICs < 4 µg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90, 0.5/1 µg/mL), and P. aeruginosa (MIC50/90, 1/2 µg/mL). Resistance to broad-spectrum cephalosporins varied from 55.3-68.5% and 14.3-28.5% among E. coli and Klebsiella spp. isolates, respectively; with ceftobiprole MIC50 > 6 µg/mL for both species. Our results showed that ceftobiprole has potent activity against staphylococci and E. faecalis, which was superior to that of vancomycin. Our data also indicates that ceftobiprole demonstrated potency comparable to that of cefepime and ceftazidime against key gram-negative species. Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most Gram-negative bacilli including Pseudomonas aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested against bacterial isolates recently collected from Brazilian private hospitals. A total of 336 unique bacterial isolates were collected from hospitalized patients between February 2008 and August 2009. Each hospital was asked to submit 100 single bacterial isolates responsible for causing blood, lower respiratory tract or skin and soft tissue infections. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using CLSI microdilution method at a central laboratory. The CLSI M100-S21 (2011) was used for interpretation of the antimicrobial susceptibility results. Among the 336 pathogens collected, 255 (75.9%) were Gram-negative bacilli and 81 (24.1%) were Gram-positive cocci. Although ceftobiprole MI[C.sub.50] values for oxacillin resistant strains were two-fold higher than for methicillin susceptible S. aureus, ceftobiprole inhibited 100% of tested S. aureus at MICs [less than or equal to] 4 [micro]g/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MI[C.sub.50/90], 0.5/1 [micro]g/mL), and P. aeruginosa (MI[C.sub.50/90], 1/2 [micro]g/mL). Resistance to broadspectrum cephalosporins varied from 55.3-68.5% and 14.3-28.5% among E. coli and Klebsiella spp. isolates, respectively; with ceftobiprole MI[C.sub.50] > 6 [micro]g/mL for both species. Our results showed that ceftobiprole has potent activity against staphylococci and E. faecalis, which was superior to that of vancomycin. Our data also indicates that ceftobiprole demonstrated potency comparable to that of cefepime and ceftazidime against key Gram-negative species. Keywords: cephalosporins; Brazil; Gram-negative aerobic bacteria; methicillin-resistant Staphylococcus aureus. Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most Gram-negative bacilli including Pseudomonas aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested against bacterial isolates recently collected from Brazilian private hospitals. A total of 336 unique bacterial isolates were collected from hospitalized patients between February 2008 and August 2009. Each hospital was asked to submit 100 single bacterial isolates responsible for causing blood, lower respiratory tract or skin and soft tissue infections. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using CLSI microdilution method at a central laboratory. The CLSI M100-S21 (2011) was used for interpretation of the antimicrobial susceptibility results. Among the 336 pathogens collected, 255 (75.9%) were Gram-negative bacilli and 81 (24.1%) were Gram-positive cocci. Although ceftobiprole MIC50 values for oxacillin resistant strains were two-fold higher than for methicillin susceptible S. aureus, ceftobiprole inhibited 100% of tested S. aureus at MICs ≤ 4 μg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90, 0.5/1 μg/mL), and P. aeruginosa (MIC50/90, 1/2 μg/mL). Resistance to broad-spectrum cephalosporins varied from 55.3–68.5% and 14.3–28.5% among E. coli and Klebsiella spp. isolates, respectively; with ceftobiprole MIC50 > 6 μg/mL for both species. Our results showed that ceftobiprole has potent activity against staphylococci and E. faecalis, which was superior to that of vancomycin. Our data also indicates that ceftobiprole demonstrated potency comparable to that of cefepime and ceftazidime against key Gram-negative species. Keywords: cephalosporins, Brazil, Gram-negative aerobic bacteria, methicillin-resistant Staphylococcus aureus Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most gram-negative bacilli including Pseudomonas aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested against bacterial isolates recently collected from Brazilian private hospitals. A total of 336 unique bacterial isolates were collected from hospitalized patients between February 2008 and August 2009. Each hospital was asked to submit 100 single bacterial isolates responsible for causing blood, lower respiratory tract or skin and soft tissue infections. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using CLSI microdilution method at a central laboratory. The CLSI M100-S21 (2011) was used for interpretation of the antimicrobial susceptibility results. Among the 336 pathogens collected, 255 (75.9%) were gram-negative bacilli and 81 (24.1%) were gram-positive cocci. Although ceftobiprole MIC50 values for oxacillin resistant strains were two-fold higher than for methicillin susceptible S. aureus, ceftobiprole inhibited 100% of tested S. aureus at MICs < 4 µg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90, 0.5/1 µg/mL), and P. aeruginosa (MIC50/90, 1/2 µg/mL). Resistance to broad-spectrum cephalosporins varied from 55.3-68.5% and 14.3-28.5% among E. coli and Klebsiella spp. isolates, respectively; with ceftobiprole MIC50 > 6 µg/mL for both species. Our results showed that ceftobiprole has potent activity against staphylococci and E. faecalis, which was superior to that of vancomycin. Our data also indicates that ceftobiprole demonstrated potency comparable to that of cefepime and ceftazidime against key gram-negative species. Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most Gram-negative bacilli including Pseudomonas aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested against bacterial isolates recently collected from Brazilian private hospitals. A total of 336 unique bacterial isolates were collected from hospitalized patients between February 2008 and August 2009. Each hospital was asked to submit 100 single bacterial isolates responsible for causing blood, lower respiratory tract or skin and soft tissue infections. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using CLSI microdilution method at a central laboratory. The CLSI M100-S21 (2011) was used for interpretation of the antimicrobial susceptibility results. Among the 336 pathogens collected, 255 (75.9%) were Gram-negative bacilli and 81 (24.1%) were Gram-positive cocci. Although ceftobiprole MI[C.sub.50] values for oxacillin resistant strains were two-fold higher than for methicillin susceptible S. aureus, ceftobiprole inhibited 100% of tested S. aureus at MICs [less than or equal to] 4 [micro]g/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MI[C.sub.50/90], 0.5/1 [micro]g/mL), and P. aeruginosa (MI[C.sub.50/90], 1/2 [micro]g/mL). Resistance to broadspectrum cephalosporins varied from 55.3-68.5% and 14.3-28.5% among E. coli and Klebsiella spp. isolates, respectively; with ceftobiprole MI[C.sub.50] > 6 [micro]g/mL for both species. Our results showed that ceftobiprole has potent activity against staphylococci and E. faecalis, which was superior to that of vancomycin. Our data also indicates that ceftobiprole demonstrated potency comparable to that of cefepime and ceftazidime against key Gram-negative species. Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most Gram-negative bacilli including Pseudomonas aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested against bacterial isolates recently collected from Brazilian private hospitals. A total of 336 unique bacterial isolates were collected from hospitalized patients between February 2008 and August 2009. Each hospital was asked to submit 100 single bacterial isolates responsible for causing blood, lower respiratory tract or skin and soft tissue infections. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using CLSI microdilution method at a central laboratory. The CLSI M100-S21 (2011) was used for interpretation of the antimicrobial susceptibility results. Among the 336 pathogens collected, 255 (75.9%) were Gram-negative bacilli and 81 (24.1%) were Gram-positive cocci. Although ceftobiprole MIC50 values for oxacillin resistant strains were two-fold higher than for methicillin susceptible S. aureus, ceftobiprole inhibited 100% of tested S. aureus at MICs≤4μg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90, 0.5/1μg/mL), and P. aeruginosa (MIC50/90, 1/2μg/mL). Resistance to broad-spectrum cephalosporins varied from 55.3–68.5% and 14.3–28.5% among E. coli and Klebsiella spp. isolates, respectively; with ceftobiprole MIC50>6μg/mL for both species. Our results showed that ceftobiprole has potent activity against staphylococci and E. faecalis, which was superior to that of vancomycin. Our data also indicates that ceftobiprole demonstrated potency comparable to that of cefepime and ceftazidime against key Gram-negative species. |
Audience | Academic |
Author | Cereda, Rosângela Ferraz Azevedo, Heber Dias Girardello, Raquel Gales, Ana C. Xavier, Danilo Elias |
Author_xml | – sequence: 1 givenname: Rosângela Ferraz surname: Cereda fullname: Cereda, Rosângela Ferraz organization: Medicine; Latin America Medical Manager at Janssen-Cilag, Brazil – sequence: 2 givenname: Heber Dias surname: Azevedo fullname: Azevedo, Heber Dias organization: Infectology; Medical Manager at Janssen-Cilag, Brazil – sequence: 3 givenname: Raquel surname: Girardello fullname: Girardello, Raquel organization: Biologist; PhD Student at the Post-graduation Course in Sciences, Universidade Federal de São Paulo (UNIFESP), Brazil – sequence: 4 givenname: Danilo Elias surname: Xavier fullname: Xavier, Danilo Elias organization: Pharmacist, PhD Student at the Post-graduation Course in Sciences, UNIFESP, Brazil – sequence: 5 givenname: Ana C. surname: Gales fullname: Gales, Ana C. email: ana.gales@gmail.com organization: Medicine; Professor of Infectology, UNIFESP, Brazil |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21861004$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkktr3DAUhU1JaR7tT2gxFPpYOJVs2Za7KZMhSQdCs-i0W3EtX80o2NJUkgPTff53NeMkNFAoWlgcvnNl6Zzj5MBYg0nympJTSmj16TtltMh4VZMPlH6sSU7yjD5LjmhV84wVDT2I-wfkMDn2_oaQvCSMvEgOc8orSgg7Su5mJuhBS2dbDX0KMuhbHbapValEFaK6cbbHFFagjQ_ppYMhM7iCyEXVdJOysV7vlQ2EtV2h8Z9Th37sg0-Vs0O6-PZzsZxls2x-frG8Ts8c_Na9BpP6MHbbl8lzBb3HV_ffk-THxfly_jW7ur5czGdXmSxJGbK6UkUhc9W1FVOQd9jQvJaAtcKSQ42lqtuGtwUhBWl4g9jSiuWybZQqAEpenCSLaW5n4UZsnB7AbYUFLfaCdSsBLmjZoyjbkinkTEY_U3XF66Ki8Xim8ppLKeOs99Os-EC_RvRBDNpL7HswaEcvOI__XLI8j-TbiVxBHKyNssGB3NFiVsSoGOd76vQfVFwdxnxi-EpH_Ynh3V-GNUIf1t72Y9DW-KdgOYExZe8dqsebUyJ2ZRL7MoldUwSlYl8mQaPvzf0Nx3bA7tH10J4IfJkAjJndanTCS41GYqcdyhAfVf_niD_-9Nnd |
CitedBy_id | crossref_primary_10_1016_j_bej_2017_04_013 crossref_primary_10_1155_2020_3852419 crossref_primary_10_1080_14787210_2021_1927711 crossref_primary_10_3109_1040841X_2014_940494 crossref_primary_10_1080_17425255_2017_1303481 crossref_primary_10_1016_j_diagmicrobio_2024_116263 crossref_primary_10_1099_jmm_0_000144 |
Cites_doi | 10.1093/jac/dkf249 10.1128/AAC.00029-07 10.1128/AAC.00044-06 10.1016/j.diagmicrobio.2008.02.008 10.1093/jac/dkg416 10.1111/j.1469-0691.2007.01725.x 10.1093/jac/dkq397 10.1016/S1473-3099(07)70109-3 10.1590/S1413-86702009000200004 10.1093/jac/dkp176 10.1128/AAC.00218-07 10.1586/14787210.6.6.805 10.1128/AAC.49.10.4210-4219.2005 10.1016/j.ajic.2009.09.012 10.1016/j.ajic.2008.03.002 |
ContentType | Journal Article |
Contributor | Ricardo, Silvana B Souza, Rosângela C Martino, Marinês D V Rosembaum, Ronaldo |
Contributor_xml | – sequence: 1 givenname: Marinês D V surname: Martino fullname: Martino, Marinês D V – sequence: 2 givenname: Ronaldo surname: Rosembaum fullname: Rosembaum, Ronaldo – sequence: 3 givenname: Silvana B surname: Ricardo fullname: Ricardo, Silvana B – sequence: 4 givenname: Rosângela C surname: Souza fullname: Souza, Rosângela C |
Copyright | 2011 Elsevier Editora Ltda. COPYRIGHT 2011 Contexto |
Copyright_xml | – notice: 2011 Elsevier Editora Ltda. – notice: COPYRIGHT 2011 Contexto |
CorporateAuthor | INVITA-A-CEFTO Brazilian Study Group |
CorporateAuthor_xml | – name: INVITA-A-CEFTO Brazilian Study Group |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION INF 7X8 DOA |
DOI | 10.1016/S1413-8670(11)70202-1 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Gale OneFile: Informe Academico MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1678-4391 |
EndPage | 348 |
ExternalDocumentID | oai_doaj_org_article_5b54fe84c2cb4f7687361f334f278ccc A343948822 10_1016_S1413_8670_11_70202_1 21861004 S1413867011702021 |
Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GeographicLocations | Brazil |
GeographicLocations_xml | – name: Brazil |
GroupedDBID | --- --K .1- .FO 0R~ 0SF 1B1 1P~ 23N 2WC 4.4 457 53G 5GY 5VS 6I. 6J9 AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAXUO ABMAC ABXHO ACGFS ADBBV ADCUG ADEZE AEGXH AENEX AEVXI AEXQZ AFCTW AFRHN AFTJW AGHFR AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APOWU AZFZN BAWUL BCNDV C1A CS3 DIK DU5 E3Z EBD EBS ECGQY EJD EMB EMOBN F5P FDB GROUPED_DOAJ GX1 HZ~ IAO IEA IHR IHW INF INH INR IPNFZ ITC IXB J1W KQ8 M41 NCXOZ O-L O9- OD- OK1 OO. P6G PV9 RIG RNS ROL RPM RSC RZL SCD SES SSZ SV3 TR2 XH2 XSB Z5R ADVLN AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c505t-76f33c2fdb64fa2de9127cae7fe58a7e5f7b98b30030989eeb1642cb9ff3aa583 |
IEDL.DBID | DOA |
ISSN | 1413-8670 |
IngestDate | Thu Sep 05 15:43:28 EDT 2024 Thu Jul 25 14:17:21 EDT 2024 Thu Feb 22 23:39:51 EST 2024 Wed Oct 25 09:50:04 EDT 2023 Tue Aug 20 22:07:52 EDT 2024 Thu Sep 26 16:17:12 EDT 2024 Sat Sep 28 07:50:07 EDT 2024 Fri Feb 23 02:20:49 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Brazil methicillin-resistant Staphylococcus aureus Gram-negative aerobic bacteria cephalosporins |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c505t-76f33c2fdb64fa2de9127cae7fe58a7e5f7b98b30030989eeb1642cb9ff3aa583 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/5b54fe84c2cb4f7687361f334f278ccc |
PMID | 21861004 |
PQID | 885055422 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_5b54fe84c2cb4f7687361f334f278ccc proquest_miscellaneous_885055422 gale_infotracmisc_A343948822 gale_infotracacademiconefile_A343948822 gale_healthsolutions_A343948822 crossref_primary_10_1016_S1413_8670_11_70202_1 pubmed_primary_21861004 elsevier_sciencedirect_doi_10_1016_S1413_8670_11_70202_1 |
PublicationCentury | 2000 |
PublicationDate | July-August 2011 2011 Jul-Aug 2011-07-00 20110701 2011-07-01 |
PublicationDateYYYYMMDD | 2011-07-01 |
PublicationDate_xml | – month: 07 year: 2011 text: July-August 2011 |
PublicationDecade | 2010 |
PublicationPlace | Brazil |
PublicationPlace_xml | – name: Brazil |
PublicationTitle | The Brazilian journal of infectious diseases |
PublicationTitleAlternate | Braz J Infect Dis |
PublicationYear | 2011 |
Publisher | Elsevier Editora Ltda Contexto Elsevier |
Publisher_xml | – name: Elsevier Editora Ltda – name: Contexto – name: Elsevier |
References | Rossolini, Dryden, Kozlov (bib14) 2011; 66 Zhanel, Voth, Nichol, Karlowsky, Noreddin, Hoban (bib15) 2009; 64 Schimith Bier, Luiz, Scheffer (bib19) 2010; 38 Noel (bib4) 2007; 13 Horan, Andrus, Dudeck (bib9) 2008; 36 (bib10) 2009 Gales, Menezes, Silbert, Sader (bib18) 2003; 52 Endimiani, Perez, Bonomo (bib1) 2008; 6 Bogdanovich, Ednie, Shapiro, Appelbaum (bib7) 2005; 49 Fritsche, Sader, Jones (bib6) 2008; 61 Doribax[package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc, 2007. Gales, Sader, Ribeiro, Zoccoli, Barth, Pignatari (bib3) 2009; 13 Davies, Page, Shang, Andrew, Kania, Bush (bib5) 2007; 51 (bib11) 2011 Yahav, Paul, Fraser, Sarid, Leibovici (bib2) 2007; 7 Bogdanovich, Clark, Ednie (bib8) 2006; 50 Andrade, Sader, Barth (bib20) 2008; 12 Jones, Deshpande, Mutnick, Biedenbach (bib16) 2002; 50 Tygacil [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc, 2005 Queenan, Shang, Kania, Page, Bush (bib17) 2007; 51 Bogdanovich (10.1016/S1413-8670(11)70202-1_bib7) 2005; 49 Yahav (10.1016/S1413-8670(11)70202-1_bib2) 2007; 7 Davies (10.1016/S1413-8670(11)70202-1_bib5) 2007; 51 Horan (10.1016/S1413-8670(11)70202-1_bib9) 2008; 36 (10.1016/S1413-8670(11)70202-1_bib10) 2009 (10.1016/S1413-8670(11)70202-1_bib11) 2011 Bogdanovich (10.1016/S1413-8670(11)70202-1_bib8) 2006; 50 Queenan (10.1016/S1413-8670(11)70202-1_bib17) 2007; 51 Gales (10.1016/S1413-8670(11)70202-1_bib3) 2009; 13 10.1016/S1413-8670(11)70202-1_bib13 Rossolini (10.1016/S1413-8670(11)70202-1_bib14) 2011; 66 Gales (10.1016/S1413-8670(11)70202-1_bib18) 2003; 52 Noel (10.1016/S1413-8670(11)70202-1_bib4) 2007; 13 Jones (10.1016/S1413-8670(11)70202-1_bib16) 2002; 50 Fritsche (10.1016/S1413-8670(11)70202-1_bib6) 2008; 61 10.1016/S1413-8670(11)70202-1_bib12 Andrade (10.1016/S1413-8670(11)70202-1_bib20) 2008; 12 Endimiani (10.1016/S1413-8670(11)70202-1_bib1) 2008; 6 Zhanel (10.1016/S1413-8670(11)70202-1_bib15) 2009; 64 Schimith Bier (10.1016/S1413-8670(11)70202-1_bib19) 2010; 38 |
References_xml | – volume: 13 start-page: 25 year: 2007 end-page: 29 ident: bib4 article-title: Clinical profile of ceftobiprole, a novel beta-lactam antibiotic publication-title: Clin Microbiol Infect contributor: fullname: Noel – volume: 61 start-page: 86 year: 2008 end-page: 95 ident: bib6 article-title: Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant publication-title: Diagn Microbiol Infect Dis contributor: fullname: Jones – volume: 13 start-page: 90 year: 2009 end-page: 98 ident: bib3 article-title: Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005–2008) publication-title: Braz J Infect Dis contributor: fullname: Pignatari – volume: 7 start-page: 338 year: 2007 end-page: 348 ident: bib2 article-title: Efficacy and safety of cefepime: a systematic review and meta-analysis publication-title: Lancet Infect Dis contributor: fullname: Leibovici – volume: 36 start-page: 309 year: 2008 end-page: 332 ident: bib9 article-title: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting publication-title: Am J Infect Control contributor: fullname: Dudeck – year: 2011 ident: bib11 article-title: Performance standards for antimicrobial susceptibility testing: 21st informational supplement – volume: 66 start-page: 151 year: 2011 end-page: 159 ident: bib14 article-title: Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study publication-title: J Antimicrob Chemother contributor: fullname: Kozlov – volume: 49 start-page: 4210 year: 2005 end-page: 4219 ident: bib7 article-title: Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin publication-title: Antimicrob Agents Chemother contributor: fullname: Appelbaum – year: 2009 ident: bib10 article-title: M7-A8 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard – volume: 50 start-page: 915 year: 2002 end-page: 932 ident: bib16 article-title: evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci publication-title: J Antimicrob Chemother contributor: fullname: Biedenbach – volume: 51 start-page: 2621 year: 2007 end-page: 2624 ident: bib5 article-title: Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, publication-title: Antimicrob Agents Chemother contributor: fullname: Bush – volume: 51 start-page: 3089 year: 2007 end-page: 3095 ident: bib17 article-title: Interactions of ceftobiprole with beta-lactamases from molecular classes A to D publication-title: Antimicrob Agents Chemother contributor: fullname: Bush – volume: 64 start-page: 364 year: 2009 end-page: 369 ident: bib15 article-title: Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant publication-title: J Antimicrob Chemother contributor: fullname: Hoban – volume: 6 start-page: 805 year: 2008 end-page: 824 ident: bib1 article-title: Cefepime: a reappraisal in an era of increasing antimicrobial resistance publication-title: Expert Rev Anti Infect Ther contributor: fullname: Bonomo – volume: 50 start-page: 2050 year: 2006 end-page: 2057 ident: bib8 article-title: Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis publication-title: Antimicrob Agents Chemother contributor: fullname: Ednie – volume: 52 start-page: 699 year: 2003 end-page: 702 ident: bib18 article-title: Dissemination in distinct Brazilian regions of an epidemic carbapenemresistant producing SPM metallo-beta-lactamase publication-title: J Antimicrob Chemother contributor: fullname: Sader – volume: 12 start-page: 3 year: 2008 end-page: 9 ident: bib20 article-title: Antimicrobial susceptibility patterns of Gram-negative bacilli isolated in Brazilian hospitals participating in the SENTRY Program (2003–2008) publication-title: Braz J Infect Dis contributor: fullname: Barth – volume: 38 start-page: 308 year: 2010 end-page: 314 ident: bib19 article-title: Temporal evolution of carbapenem-resistant publication-title: Am J Infect Control contributor: fullname: Scheffer – volume: 50 start-page: 915 issue: 6 year: 2002 ident: 10.1016/S1413-8670(11)70202-1_bib16 article-title: In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkf249 contributor: fullname: Jones – volume: 51 start-page: 2621 issue: 7 year: 2007 ident: 10.1016/S1413-8670(11)70202-1_bib5 article-title: Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00029-07 contributor: fullname: Davies – volume: 50 start-page: 2050 issue: 6 year: 2006 ident: 10.1016/S1413-8670(11)70202-1_bib8 article-title: Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00044-06 contributor: fullname: Bogdanovich – volume: 61 start-page: 86 issue: 1 year: 2008 ident: 10.1016/S1413-8670(11)70202-1_bib6 article-title: Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006) publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2008.02.008 contributor: fullname: Fritsche – year: 2009 ident: 10.1016/S1413-8670(11)70202-1_bib10 – volume: 52 start-page: 699 issue: 4 year: 2003 ident: 10.1016/S1413-8670(11)70202-1_bib18 article-title: Dissemination in distinct Brazilian regions of an epidemic carbapenemresistant producing SPM metallo-beta-lactamase publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkg416 contributor: fullname: Gales – volume: 13 start-page: 25 issue: Suppl2 year: 2007 ident: 10.1016/S1413-8670(11)70202-1_bib4 article-title: Clinical profile of ceftobiprole, a novel beta-lactam antibiotic publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2007.01725.x contributor: fullname: Noel – volume: 66 start-page: 151 issue: 1 year: 2011 ident: 10.1016/S1413-8670(11)70202-1_bib14 article-title: Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkq397 contributor: fullname: Rossolini – volume: 7 start-page: 338 issue: 5 year: 2007 ident: 10.1016/S1413-8670(11)70202-1_bib2 article-title: Efficacy and safety of cefepime: a systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(07)70109-3 contributor: fullname: Yahav – volume: 13 start-page: 90 issue: 2 year: 2009 ident: 10.1016/S1413-8670(11)70202-1_bib3 article-title: Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005–2008) publication-title: Braz J Infect Dis doi: 10.1590/S1413-86702009000200004 contributor: fullname: Gales – volume: 64 start-page: 364 issue: 2 year: 2009 ident: 10.1016/S1413-8670(11)70202-1_bib15 article-title: Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkp176 contributor: fullname: Zhanel – year: 2011 ident: 10.1016/S1413-8670(11)70202-1_bib11 – ident: 10.1016/S1413-8670(11)70202-1_bib12 – volume: 51 start-page: 3089 issue: 9 year: 2007 ident: 10.1016/S1413-8670(11)70202-1_bib17 article-title: Interactions of ceftobiprole with beta-lactamases from molecular classes A to D publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00218-07 contributor: fullname: Queenan – ident: 10.1016/S1413-8670(11)70202-1_bib13 – volume: 6 start-page: 805 issue: 6 year: 2008 ident: 10.1016/S1413-8670(11)70202-1_bib1 article-title: Cefepime: a reappraisal in an era of increasing antimicrobial resistance publication-title: Expert Rev Anti Infect Ther doi: 10.1586/14787210.6.6.805 contributor: fullname: Endimiani – volume: 49 start-page: 4210 issue: 10 year: 2005 ident: 10.1016/S1413-8670(11)70202-1_bib7 article-title: Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.49.10.4210-4219.2005 contributor: fullname: Bogdanovich – volume: 38 start-page: 308 issue: 4 year: 2010 ident: 10.1016/S1413-8670(11)70202-1_bib19 article-title: Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil publication-title: Am J Infect Control doi: 10.1016/j.ajic.2009.09.012 contributor: fullname: Schimith Bier – volume: 36 start-page: 309 issue: 5 year: 2008 ident: 10.1016/S1413-8670(11)70202-1_bib9 article-title: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting publication-title: Am J Infect Control doi: 10.1016/j.ajic.2008.03.002 contributor: fullname: Horan – volume: 12 start-page: 3 issue: Suppl 2 year: 2008 ident: 10.1016/S1413-8670(11)70202-1_bib20 article-title: Antimicrobial susceptibility patterns of Gram-negative bacilli isolated in Brazilian hospitals participating in the SENTRY Program (2003–2008) publication-title: Braz J Infect Dis contributor: fullname: Andrade |
SSID | ssj0025040 |
Score | 1.9571791 |
Snippet | Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most... |
SourceID | doaj proquest gale crossref pubmed elsevier |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | 339 |
SubjectTerms | Anti-Bacterial Agents - pharmacology Brazil Cephaloridine Cephalosporins Cephalosporins - pharmacology Gram-negative aerobic bacteria Gram-Negative Bacteria - drug effects Gram-Negative Bacteria - isolation & purification Gram-Positive Bacteria - drug effects Gram-Positive Bacteria - isolation & purification Health aspects Humans Infection methicillin-resistant Staphylococcus aureus Microbial Sensitivity Tests - methods Moxalactam |
SummonAdditionalLinks | – databaseName: ScienceDirect Free and Delayed Access Journal dbid: IXB link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELVWe0BcEN8UFvABCTiYNo0TO9zSassu0i4Huqg3y3bsKhKbVGl64c7_ZsZJg7IXJK6TkZN4xuOZZN4zIe-QcwypwJhIrWU8iTTLjJyxYsaN0ZAzZzNEI19dpxc3_Osm2ZyQ5RELg22VfezvYnqI1r1k2s_mdFeW0-8RxF-ZCiQ1g5wngMmR2xNBfJvFUHQlsw4UCcoMtf-ieLoRgvBDFH0Mg7BotD8FGv_RNnU3bt_JRsOutHpIHvTpJM27J35ETlz1mNy76n-YPyG_86otb8vAtgR6iGLAwyJo7al1HhZzucP-Qqq3uoREkX5p9C2r3DbQgVNdFZ2ka-0CCR5gXIPP7T9TqNMPP9s9RYAKvbz-cbnOWc6W56v1N7po9K8SP6DQQF_7lNysztfLC9afvMAsZEQtGM7HsZ37wqTc63nhsmgurHbCu0Rq4RIvTCZNHH6kysxBwIc6xprM-1jrRMbPyGlVV-4FoVFRpCIzNhOx5TPHNToFVEmGizjWkZiQT8f5VruOYEMNnWdoIIUGgkJFBQOpaEIWaJVBGfmxg6Butqp3EJWYhHsnuYWH4h5KKhGnEbwT93MhrbUTIo82VSN3g6HKf93_LfqA6nCqQ4BQeYwgYyhY5hPyPmhgiGgbbXWPdIAJQbKtkebZSBOWth1dpkc_U3gJ--EqVx_2SkqwU8JR5Xnnf8N84CFjSAP48v9f8RW53306x67kM3LaNgf3GnKv1rwJi-sPWZslIA priority: 102 providerName: Elsevier |
Title | Antimicrobial activity of ceftobiprole against Gram-negative and Gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study |
URI | https://dx.doi.org/10.1016/S1413-8670(11)70202-1 https://www.ncbi.nlm.nih.gov/pubmed/21861004 https://search.proquest.com/docview/885055422 https://doaj.org/article/5b54fe84c2cb4f7687361f334f278ccc |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4s1CAR-QgINpHk7scMtWXbpILQe2aG-W7dhVpDZb7WYv3PnfzNjZhfTSC5ccnNFuNDMef5PMfEPIe-QcQyowJkprGS9SzSojE9Yk3BgNmLlKsBv57Lw8veDflsXyn1FfWBMW6YGj4o4KU3DvJLeZNdwDOBZ5mfo85z4T0lobom9a7JKpIdUqktgKCSGayVIkf3t3jn7sFz-m6ScBcClj6ehUCuT9o8PpdrS-hUHDWTR7RB4OIJLW8eEfk3uue0Lunw2fyZ-S33XXt9dt4FgCOexdwBERdOWpdR62cHuDVYVUX-oW4CH9utbXrHOXgQSc6q6JK7GgC1ZwbPEKPG3zhUJ2vr3qNxTbUuj8_Od8UbOaHZ_MFt_pdK1_tfjahAbS2mfkYnayOD5lw7wFZgEH9WAu0KvNfGNK7nXWuCrNhNVOeFdILVzhhamkycPnU1k5CPOQvVhTeZ9rXcj8OTnoVp17SWjaNKWojK1EbnniuEZXgNzIcJHnOhUT8nmnb3UTaTXUvt4MDaTQQJCeqGAglU7IFK2yF0ZW7LAAvqIGX1F3-cqEyJ1N1QAwInCAn2rv-v936AMqdqfuw4Kqc2wthjQlm5APQQIDQ7_WVg_9DaAQpNgaSR6OJGFD29FtuvMzhbewCq5zq-1GSQl2KjiKvIj-t9cHjhZD8r9X_0NPr8mD-Oocq5IPyUG_3ro3gL168zZsM7jOl9M_GkcmWA |
link.rule.ids | 315,786,790,870,2115,3525,27957,27958,45909 |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELVWiwRcEN8UFtYHJOBgNmmc2OHWVlta2JYDXdSbZTt2FYlNqza9cOd_M-OkRdkLEtfJyEk84_FMMu-ZkLfIOYZUYExk1jKexprlRkasiLgxGnLmPEI08myeTa75l2W6PCGjAxYG2yrb2N_E9BCtW8lFO5sXm7K8-B5D_JWZQFIzyHkQTH6Hp3mErj1dDo9VVxo1qEjQZqj-F8bTDBGE7-P4QxiFxZ0NKvD4d_ap24H7VjoatqXxQ_KgzSfpoHnkR-TEVY_J3Vn7x_wJ-T2o6vKmDHRLoIcwBjwtgq49tc7Dai432GBI9UqXkCnSz1t9wyq3CnzgVFdFI2l6u0CCJxivwel2nygU6vuf9Y4iQoVO5z-miwEbsNHlePGNDrf6V4lfUGjgr31KrseXi9GEtUcvMAspUQ2W80li-74wGfe6X7g87gurnfAulVq41AuTS5OEP6kydxDxoZCxJvc-0TqVyTNyWq0r94LQuCgykRubi8TyyHGNXgFlkuEiSXQseuTjYb7VpmHYUMfWMzSQQgNBpaKCgVTcI0O0ylEZCbKDYL1dqdZDVGpS7p3kFh6Ke6ipRJLF8E7c94W01vaIPNhUdfwNhir_df9z9AHVAFWPEUINEkQZQ8XS75F3QQNjRL3VVrdQB5gQZNvqaJ51NGFt285levAzhZewIa5y6_1OSQl2SjmqPG_87zgfeMoY8gC-_P9XPCf3JovZlbqazr--Iveb7-jYonxGTuvt3r2GRKw2b8JC-wMtDChH |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antimicrobial+activity+of+ceftobiprole+against+Gram-negative+and+Gram-positive+pathogens%3A+results+from+INVITA-A-CEFTO+Brazilian+study&rft.jtitle=The+Brazilian+journal+of+infectious+diseases&rft.au=Cereda%2C+Ros%C3%A2ngela+Ferraz&rft.au=Azevedo%2C+Heber+Dias&rft.au=Girardello%2C+Raquel&rft.au=Xavier%2C+Danilo+Elias&rft.date=2011-07-01&rft.issn=1413-8670&rft.volume=15&rft.issue=4&rft.spage=339&rft.epage=348&rft_id=info:doi/10.1016%2FS1413-8670%2811%2970202-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S1413_8670_11_70202_1 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1413-8670&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1413-8670&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1413-8670&client=summon |